Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | S Tjulandin, M Fedyanin, L Demidov, V Moiseyenko, S Protsenko, S Odintsova, T Y Semiglazova, R Zukov, S Lazarev, A Andreev, M Nechaeva, J Makarova, N Fadeeva, A Tarasova, O Kozlova, M Shustova, A Garipov, R Ivanov | ||||||||||||
Title | Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma | ||||||||||||
|
|||||||||||||
URL | https://academic.oup.com/annonc/article-abstract/30/Supplement_11/mdz451.027/5675195?redirectedFrom=fulltext | ||||||||||||
Abstract Text | Annals of Oncology, Volume 30, Issue Supplement_11, December 2019, Abstract 119P |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Prolgolimab | Prolgolimab | 0 | 0 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Prolgolimab | BCD-100|BCD100|BCD 100 | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 117 | Prolgolimab (BCD-100) is a monoclonal antibody against PD-1, which may promote anti-tumor immune response (Annals of Oncology, Volume 30, Issue Supplement_11, December 2019, Abstract 119P, PMID: 31847708). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|